Tuesday , October 26 2021

Glenmark aims consolidated revenue growth of 12-15% over next 3-5 years

Glenmark Pharmaceuticals is aiming a consolidated revenue growth of 12-15% over the next 3-5 years, on account of strengthening the current business of generics, branded generics, anticipated launch of dermatology and respiratory specialty products during 2019-2022, and new molecular entity (NME) products from 2023 onwards.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'